Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

arter ending March 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward- looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise these statements.

Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.


    Media Contact:            Investor Contact:

    Maria Cantor              Sally Curley

    (617) 768-6690            (617) 768-6140

CONTACT: Media, Maria Cantor, +1-617-768-6690; Investors, Sally Curley,+1-617-768-6140, both of Genzyme Corp.

Web site: http://www.genzyme.com//

Company News On-Call: http://www.prnewswire.com/comp/113803.html /

Ticker Symbol: (NASDAQ-NMS:GENZ)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/29/2009)...ire/ -- FUJIFILM Medical Systems USA, Inc., the wo...) with over 7,000 installations, is pleased to deb...n the US. The Aspire HD combines the use of advan...ration detector technology and the smallest pixel ...olution at a reduced dose for the patient. The fl...
(Date:11/28/2009)...re/ -- Siemens Healthcare redefines productivity ...aging matrix) technology and with its new Dot(TM) ...ies are introduced in the new MAGNETOM ® Aer...anners at the 95th Scientific Assembly and Annual ...ca (RSNA) from November 29 to December 3 at McCorm...
(Date:11/27/2009)...wire/ -- At the upcoming Radiological Society of N..., Royal Philips Electronics ( PHG, AEX: PHI) will ...informatics solutions designed to directly address... delivering meaningful imaging innovations that re... easy upgradability. This focus will enable Phili...
Breaking Medicine Technology:FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 2FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 3FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 4Siemens Introduces Its New Power Couple at RSNA 2009 2Siemens Introduces Its New Power Couple at RSNA 2009 3Siemens Introduces Its New Power Couple at RSNA 2009 4Siemens Introduces Its New Power Couple at RSNA 2009 5Siemens Introduces Its New Power Couple at RSNA 2009 6Siemens Introduces Its New Power Couple at RSNA 2009 7Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4Wyeths Prevenar 13 Receives First Approval 51609 1Wyeths Prevenar 13 Receives First Approval 51609 2Wyeths Prevenar 13 Receives First Approval 51609 3Wyeths Prevenar 13 Receives First Approval 51609 4Wyeths Prevenar 13 Receives First Approval 51609 5Julie Stav Reminds Hispanic Moms to Invest in Their Familys Wellness with Milk 21 51606 1Julie Stav Reminds Hispanic Moms to Invest in Their Familys Wellness with Milk 21 51606 2Julie Stav Reminds Hispanic Moms to Invest in Their Familys Wellness with Milk 21 51606 3Looking to Shape Up for Summer 3F The Solution May Be the Steps Youre Already Taking 51603 1Looking to Shape Up for Summer 3F The Solution May Be the Steps Youre Already Taking 51603 2Looking to Shape Up for Summer 3F The Solution May Be the Steps Youre Already Taking 51603 3
...wide, MENLO PARK, Calif., Nov. 15 Cogentus Pharm...global Phase III clinical program to,evaluate the ...py CGT-2168.,The program, which includes the COGEN...tients at hundreds of sites in the United States, ...ww.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO ...
... 15 BiPar,Sciences, Inc., a privately held biopha...ies, today announced it has initiated a Phase 2 st...ts with triple-negative breast,cancer that do not ...rs. The company designed the Phase 2 trial in thi...l need-based on molecular biomarker data,presented...
Other Medicine Technology:Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 3
(Date:11/29/2009)... form between brain cells almost immediately as an...shed this week in Nature . Led by researchers at ...y involved detailed observations of the rewiring p... learning. , The researchers studied mice as the...ed. They observed rapid growth of structures that ...
(Date:11/29/2009)...equals a $41,000 pay raise, researchers say , ...hological therapy may be much more effective at ma...a lottery prize, suggests an English study. , R...o provided information about their mental well-bei... $1,329 course of therapy was so significant that ...
(Date:11/29/2009)...care,s uncertain future and rising costs open the ...dable Acupuncture Scottsdale answers the call. , ...-- Affordable Acupuncture, LLC opened in Scottsdal...h enthusiasm and gratitude. Its increasing popular...ngs, need and cost. "As far as I’m con...
(Date:11/28/2009)...r change after 30-minute psychosocial intervention...hDay News) -- A program that gets persistent drunk...ngerous behavior may lead to significant and long-...new study included 184 men and women with two or m...andomly assigned to one of two interventions. The ...
(Date:11/27/2009)...wire-FirstCall/ -- GSI Group Inc. (Pink Sheets: GS...ology products and semiconductor systems, today an...areholders has been scheduled for Friday, April 30... be announced in due course. As previously announ...m Stephen Bershad, a holder of greater than ten pe...
Breaking Medicine News(10 mins):Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Psychotherapy Can Boost Happiness More Than Money: Study 2Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:GSI Group Calls Shareholders Meeting 2
...have launched a public awareness campaign warning ...ess-skilled non-physicians performing the procedur...going procedures like Botox injections, laser hair...n some cases. The American Society of Derma...
... lifestyles and environmental changes have caused ...e. They represent 17% of the childhood cancer case... between 1978 and 1997 in 15 European countries we... the age of 14. Majority of the childhood canc...
...d’, a new oral drug that is being developed for mu...he new study has suggests that the experimental dr...ts with relapsing multiple sclerosis. It was also ...patients with MS the first effective treatment in ...
... have more urinary problems than white men, but ar...ology study that was conducted on over 8,000 men h...ology journal BJU International, states that South... in Leicestershire, UK, were randomly selected fro...
...t medical trusts facing major losses to outsource ... one million pounds a year.// Around 60 speci...sourcing. Hospitals in Leeds are reported to be fa...have been fiercely criticised by union leaders, MP...
...gram developed by researchers now at the Universit...e used to study how individuals with sickle cell d...erited blood disorder.// The $2.9 million f...to educate them about pain management and provide ...
Other Medicine News:Health News:Campaign Against Cosmetic Surgeries Performed By Less-Skilled Non-physicians Launched 2Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2Health News:An Experimental New Drug Might Be Effective In Treating MS 2Health News:South Asian Men Have More Urinary Problems Than White Men 2Health News:Leeds Hospitals to Outsource Medical Transcription Work to India 2Health News:Computer May Improve Pain Relief for Sickle Cell Patients 2
HDL Cholesterol (PEG)
Cholesterol/HDL
HDL-Cholesterol Direct Reagent
HDL Cholesterol
Medicine Products: